NIH Weekly Funding Opportunities and Policy Notices

Notice of Correction for RFA-MH-18-707, "Confirmatory Efficacy Clinical Trials of Non-Pharmacological Interventions for Mental Disorders (R01 Clinical Trial Required)"
Monday, February 4, 2019 - 10:48am
Notice NOT-MH-19-020 from the NIH Guide for Grants and Contracts
Notice of Correction for RFA-MH-18-702 "Early Stage Testing of Pharmacologic or Device-based Interventions for the Treatment of Mental Disorders (R61/R33- Clinical Trial Required)"
Monday, February 4, 2019 - 10:36am
Notice NOT-MH-19-016 from the NIH Guide for Grants and Contracts
Notice of Correction for RFA-MH-18-700 "Clinical Trials to Test the Effectiveness of Treatment, Preventive and Services Interventions (Collaborative R01 Clinical Trial Required)"
Monday, February 4, 2019 - 10:32am
Notice NOT-MH-19-014 from the NIH Guide for Grants and Contracts
Notice of Correction for RFA-MH-18-704 "Development of Psychosocial Therapeutic and Preventive Interventions for Mental Disorders (R61/R33- Clinical Trial Required)"
Monday, February 4, 2019 - 10:24am
Notice NOT-MH-19-017 from the NIH Guide for Grants and Contracts
Notice of Correction for RFA-MH-18-705, "Development of Psychosocial Therapeutic and Preventive Interventions for Mental Disorders (R33 Clinical Trial Required)"
Monday, February 4, 2019 - 10:16am
Notice NOT-MH-19-018 from the NIH Guide for Grants and Contracts
Notice of Correction for RFA-MH-18-701 "Clinical Trials to Test the Effectiveness of Treatment, Preventive and Services Interventions (R01 Clinical Trial Required)"
Monday, February 4, 2019 - 10:11am
Notice NOT-MH-19-015 from the NIH Guide for Grants and Contracts
Notice of Correction for RFA-MH-18-706, "Pilot Effectiveness Trials for Treatment, Preventive and Services Interventions (R34- Clinical Trial Required)"
Monday, February 4, 2019 - 10:05am
Notice NOT-MH-19-019 from the NIH Guide for Grants and Contracts
Notice of Participation of the National Institute on Alcohol Abuse and Alcoholism (NIAAA) in PAR-19-146 "Drug Discovery For Nervous System Disorders (R21 Clinical Trials Not Allowed)"
Monday, February 4, 2019 - 9:19am
Notice NOT-AA-19-008 from the NIH Guide for Grants and Contracts
Notice of Participation of the National Institute on Alcohol Abuse and Alcoholism (NIAAA) in PAR-19-147 "Drug Discovery For Nervous System Disorders (R01 Clinical Trials Not Allowed)"
Monday, February 4, 2019 - 9:01am
Notice NOT-AA-19-007 from the NIH Guide for Grants and Contracts
Notice to Extend PAR-19-027, "Basic Neurodevelopmental Biology of Circuits and Behavior (R01 Clinical Trial Not Allowed)"
Monday, February 4, 2019 - 6:49am
Notice NOT-MH-18-071 from the NIH Guide for Grants and Contracts
Notice to Extend, PAR-19-028 "Basic Neurodevelopmental Biology of Brian Circuits and Behavior (R21 Clinical Trial Not Allowed)
Monday, February 4, 2019 - 6:41am
Notice NOT-MH-18-072 from the NIH Guide for Grants and Contracts
Notice of Change to IC and NIH Office of Interest Areas and Specific Requirements for RFA-NS-19-009 "Promoting Research on Music and Health: Fundamentals and Applications (R21 Clinical Trial Optional)"
Monday, February 4, 2019 - 6:32am
Notice NOT-NS-19-035 from the NIH Guide for Grants and Contracts
Notice of Change to Council Dates for PAR-19-143 "NIDCD Research Career Enhancement Award for Established Investigators (K18 Independent Basic Experimental Studies with Humans Required)"
Monday, February 4, 2019 - 6:09am
Notice NOT-DC-19-006 from the NIH Guide for Grants and Contracts
Refinement and Testing of Interventions to Sustain ADHD Treatment Effects Across Settings and Developmental Transitions (R34 Clinical Trial Required)
Monday, February 4, 2019 - 12:21am
Funding Opportunity RFA-MH-20-100 from the NIH Guide for Grants and Contracts. NIMH seeks applications for pilot projects to evaluate the preliminary effectiveness of augmented or modified interventions designed to promote sustained improvement in attention-deficit/hyperactivity disorder (ADHD) symptoms and functional impairments across settings and transitions in children, adolescents, and young adults. An emphasis is placed on trials that go beyond seeking incremental gains in intervention effects, and instead take a theory-driven, empirical approach to applying modifications that will have a significant and enduring impact on functioning. In this pilot phase of effectiveness research, the trial should be designed to evaluate the feasibility, tolerability, acceptability, safety, and potential effectiveness of the approach; to address whether the intervention engages the target mechanism(s) presumed to underlie the intervention effects; and to obtain necessary preliminary data as a pre-requisite to a larger-scale, definitive effectiveness trial.
Pre-Solicitation Notice: NIAID Clinical Research Products Management Center
Friday, February 1, 2019 - 10:49am
Notice NOT-AI-19-039 from the NIH Guide for Grants and Contracts
Notice of NIAID Research Objectives added to PAR-18-714 Academic Research Enhancement Award for Undergraduate-Focused Institutions (R15 - Clinical Trial Not Allowed)
Friday, February 1, 2019 - 10:45am
Notice NOT-AI-19-038 from the NIH Guide for Grants and Contracts
Notice of NIAID Research Objectives added to PAR-19-134 Research Enhancement Award Program (REAP) for Health Professional Schools and Graduate Schools (R15 Clinical Trial Not Allowed)
Friday, February 1, 2019 - 10:39am
Notice NOT-AI-19-037 from the NIH Guide for Grants and Contracts
NCI Awardee Skills Development Consortium: Research Education Short Courses (UE5 Clinical Trial Not Allowed)
Friday, February 1, 2019 - 8:43am
Funding Opportunity RFA-CA-19-010 from the NIH Guide for Grants and Contracts. The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The over-arching goal of this National Cancer Institute (NCI) UE5 R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nations biomedical, behavioral and clinical cancer research needs. This UE5 funding opportunity announcement (FOA) is a part of the National Cancer Institute (NCI) initiative to establish the "NCI Awardee Skills Development Consortium (NASDC)." The major objective of this initiative is to provide opportunities for current NCI grantees, especially those who are junior faculty (e.g., assistant professors, instructors, research scientists, or equivalent), to enhance their skills in areas that are critical for establishing and maintaining successful independent academic cancer research careers
NCI Awardee Skills Development Consortium: Program Logistics and Evaluation Coordinating Center (U24 Clinical Trial Not Allowed)
Friday, February 1, 2019 - 8:43am
Funding Opportunity RFA-CA-19-011 from the NIH Guide for Grants and Contracts. This U24 funding opportunity announcement (FOA) is a part of the National Cancer Institute (NCI) initiative to establish the "NCI Awardee Skills Development Consortium (NASDC)." The overarching goal of this initiative is to provide opportunities for current NCI grantees, especially those who are junior faculty (e.g., assistant professors, instructors, research scientists, or equivalent), to enhance their skills in areas that are critical for establishing and maintaining successful independent academic cancer research careers. This U24 FOA solicits applications for a Coordinating Center to address the NASDC logistics and evaluation needs in serving the NASDC Research Education Short Courses that will be supported by a companion UE5 FOA RFA-CA-19-010). The various logistic and evaluation activities and roles of the U24 NASDC Coordinating Center include, but are not limited to, working together with the UE5 Research Education Short Course awardees on advertising the NASDC Short Courses and recruiting participants; providing logistic support during course implementation; arranging periodic NASDC Steering Committee in-person meetings and teleconferences and preparing summary minutes; and assuming a primary role in the evaluation of the NASDC Courses and overall program.
Notice of Clarification in Eligibility Requirements for PAR-19-098 Emerging Global Leader Award (K43 Independent Clinical Trial Not Allowed) and PAR-19-051 Emerging Global Leader Award (K43 Independent Clinical Trial Required)
Friday, February 1, 2019 - 7:43am
Notice NOT-TW-19-002 from the NIH Guide for Grants and Contracts

Pages